Broderick Brian C Lowers Stock Position in Cigna Group $CI

Broderick Brian C cut its stake in shares of Cigna Group (NYSE:CI) by 10.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 851 shares of the health services provider’s stock after selling 100 shares during the period. Broderick Brian C’s holdings in Cigna Group were worth $281,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Valeo Financial Advisors LLC lifted its stake in Cigna Group by 86,071.1% during the second quarter. Valeo Financial Advisors LLC now owns 3,475,282 shares of the health services provider’s stock worth $1,148,859,000 after purchasing an additional 3,471,249 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Cigna Group in the first quarter valued at $727,905,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Cigna Group by 10.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,056,806 shares of the health services provider’s stock valued at $3,966,690,000 after buying an additional 1,094,327 shares during the period. GQG Partners LLC lifted its stake in Cigna Group by 21.5% during the 1st quarter. GQG Partners LLC now owns 4,886,674 shares of the health services provider’s stock worth $1,607,716,000 after acquiring an additional 865,092 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Cigna Group by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,649,837 shares of the health services provider’s stock valued at $542,796,000 after acquiring an additional 457,052 shares during the period. 86.99% of the stock is currently owned by institutional investors and hedge funds.

Cigna Group Stock Performance

Shares of CI stock opened at $307.21 on Wednesday. The company has a market cap of $82.00 billion, a P/E ratio of 16.77, a PEG ratio of 0.89 and a beta of 0.45. The firm has a fifty day moving average price of $292.94 and a 200 day moving average price of $309.54. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 0.65. Cigna Group has a 12 month low of $256.89 and a 12 month high of $358.88.

Cigna Group (NYSE:CI) last announced its quarterly earnings results on Thursday, July 31st. The health services provider reported $7.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.15 by $0.05. The company had revenue of $67.13 billion during the quarter, compared to the consensus estimate of $62.61 billion. Cigna Group had a return on equity of 18.80% and a net margin of 1.92%.Cigna Group’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period in the previous year, the business earned $6.72 EPS. Cigna Group has set its FY 2025 guidance at 29.600- EPS. Sell-side analysts predict that Cigna Group will post 29.77 earnings per share for the current fiscal year.

Cigna Group Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 18th. Shareholders of record on Thursday, September 4th were paid a $1.51 dividend. This represents a $6.04 annualized dividend and a yield of 2.0%. The ex-dividend date was Thursday, September 4th. Cigna Group’s dividend payout ratio is currently 32.97%.

Insider Activity at Cigna Group

In related news, insider Brian C. Evanko sold 5,368 shares of the stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $300.00, for a total value of $1,610,400.00. Following the transaction, the insider directly owned 51,182 shares of the company’s stock, valued at $15,354,600. This trade represents a 9.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Nicole S. Jones sold 28,526 shares of the business’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $300.00, for a total transaction of $8,557,800.00. Following the completion of the sale, the insider directly owned 25,648 shares of the company’s stock, valued at approximately $7,694,400. This trade represents a 52.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. TD Cowen upgraded shares of Cigna Group to a “strong-buy” rating in a research note on Monday, June 23rd. Robert W. Baird set a $372.00 target price on shares of Cigna Group in a research note on Thursday, August 14th. Guggenheim reissued a “buy” rating and issued a $350.00 price target (down previously from $388.00) on shares of Cigna Group in a research report on Monday, August 4th. Royal Bank Of Canada restated an “outperform” rating and issued a $371.00 price target on shares of Cigna Group in a research note on Thursday, June 26th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Cigna Group in a research note on Saturday, September 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Cigna Group has an average rating of “Moderate Buy” and a consensus target price of $372.69.

Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.